Advanced search
1 file | 285.65 KB Add to list

Current state of mRNA vaccine development against Mycobacterium tuberculosis

Ilke Aernout (UGent) , Rein Verbeke (UGent) , Stefaan De Smedt (UGent) , Francis Impens (UGent) and Ine Lentacker (UGent)
Author
Organization
Project
Abstract
Tuberculosis (TB) disease caused by Mycobacterium tuberculosis (Mtb) is currently the second leading cause of death by a single infectious organism. Due to the increasing antimicrobial resistance (AMR) of Mtb, there is a high need for the development of more effective vaccines. In this chapter, we provide an in-depth overview of the potential of mRNA vaccines in the context of TB. Moreover, we present a comprehensive overview of the current state of the art and clinical development of mRNA vaccines against TB.
Keywords
mRNA vaccines, Mycobacterium tuberculosis, correlates of protection, antigen discovery, antimicrobial resistance, mRNA-LNPs, tuberculosis, bacterial vaccines, immune response, BCG

Downloads

  • (...).docx
    • full text (Accepted manuscript)
    • |
    • UGent only
    • |
    • Word
    • |
    • 285.65 KB

Citation

Please use this url to cite or link to this publication:

MLA
Aernout, Ilke, et al. “Current State of MRNA Vaccine Development against Mycobacterium Tuberculosis.” Trends in MRNA Vaccine Research, edited by Gabor Tamas Szabo and Norbert Pardi, Wiley-VCH, 2025, pp. 325–35, doi:10.1002/9783527838394.ch12.
APA
Aernout, I., Verbeke, R., De Smedt, S., Impens, F., & Lentacker, I. (2025). Current state of mRNA vaccine development against Mycobacterium tuberculosis. In G. T. Szabo & N. Pardi (Eds.), Trends in mRNA vaccine research (pp. 325–335). https://doi.org/10.1002/9783527838394.ch12
Chicago author-date
Aernout, Ilke, Rein Verbeke, Stefaan De Smedt, Francis Impens, and Ine Lentacker. 2025. “Current State of MRNA Vaccine Development against Mycobacterium Tuberculosis.” In Trends in MRNA Vaccine Research, edited by Gabor Tamas Szabo and Norbert Pardi, 325–35. Weinheim: Wiley-VCH. https://doi.org/10.1002/9783527838394.ch12.
Chicago author-date (all authors)
Aernout, Ilke, Rein Verbeke, Stefaan De Smedt, Francis Impens, and Ine Lentacker. 2025. “Current State of MRNA Vaccine Development against Mycobacterium Tuberculosis.” In Trends in MRNA Vaccine Research, ed by. Gabor Tamas Szabo and Norbert Pardi, 325–335. Weinheim: Wiley-VCH. doi:10.1002/9783527838394.ch12.
Vancouver
1.
Aernout I, Verbeke R, De Smedt S, Impens F, Lentacker I. Current state of mRNA vaccine development against Mycobacterium tuberculosis. In: Szabo GT, Pardi N, editors. Trends in mRNA vaccine research. Weinheim: Wiley-VCH; 2025. p. 325–35.
IEEE
[1]
I. Aernout, R. Verbeke, S. De Smedt, F. Impens, and I. Lentacker, “Current state of mRNA vaccine development against Mycobacterium tuberculosis,” in Trends in mRNA vaccine research, G. T. Szabo and N. Pardi, Eds. Weinheim: Wiley-VCH, 2025, pp. 325–335.
@incollection{01JJRX862RSGAG1DV39KJYAGNW,
  abstract     = {{Tuberculosis (TB) disease caused by Mycobacterium tuberculosis (Mtb) is currently the second leading cause of death by a single infectious organism. Due to the increasing antimicrobial resistance (AMR) of Mtb, there is a high need for the development of more effective vaccines. In this chapter, we provide an in-depth overview of the potential of mRNA vaccines in the context of TB. Moreover, we present a comprehensive overview of the current state of the art and clinical development of mRNA vaccines against TB.}},
  author       = {{Aernout, Ilke and Verbeke, Rein and De Smedt, Stefaan and Impens, Francis and Lentacker, Ine}},
  booktitle    = {{Trends in mRNA vaccine research}},
  editor       = {{Szabo, Gabor Tamas and Pardi, Norbert}},
  isbn         = {{9783527350582}},
  keywords     = {{mRNA vaccines,Mycobacterium tuberculosis,correlates of protection,antigen discovery,antimicrobial resistance,mRNA-LNPs,tuberculosis,bacterial vaccines,immune response,BCG}},
  language     = {{eng}},
  pages        = {{325--335}},
  publisher    = {{Wiley-VCH}},
  title        = {{Current state of mRNA vaccine development against Mycobacterium tuberculosis}},
  url          = {{http://doi.org/10.1002/9783527838394.ch12}},
  year         = {{2025}},
}

Altmetric
View in Altmetric